CASRAI Dictionary

Tag: annual research integrity statement

  • Retraction Watch Database: Hiring Due Diligence

    The Retraction Watch Database (RWDB) lets research offices, tenure committees and funders check whether a candidate’s published papers carry a retraction, correction or expression of concern. Used properly — combined with author, affiliation, article-type or date-range search fields, cross-checked against ORI case summaries, and read for the stated reason rather than the bare fact of a hit — it becomes a genuine due-diligence tool rather than a source of false alarms.

    The Retraction Watch Database is a free, searchable index of scholarly retractions, corrections and expressions of concern, built by the Center for Scientific Integrity and distributed with Crossref. It is the largest curated source of retraction metadata available, but it indexes withdrawn papers, not people — why due diligence needs more than a name search.

    What Is the Retraction Watch Database, Exactly?

    RWDB is a structured dataset, not a blog archive: each entry records the original article, the notice, the stated reason, and the author/affiliation strings as printed on the paper. As of mid-2026 it logs more than 65,000 retraction entries. Crossref took on distribution in 2023, publishing the full CSV through a public repository rather than only the web form — the hosted interface at retractiondatabase.org suits one-off lookups; the download suits batch screening.

    Critically, RWDB does not aim for completeness on corrections and expressions of concern the way it does for retractions. Its own user guide states EOCs and corrections are entered mainly “as they relate to existing retractions, blog posts, or high-profile studies” — a clean result there is not evidence of a clean record.

    Search by author name first, narrow by affiliation, then confirm with PMID or DOI. Since 23 October 2024, RWDB has required every search to include at least one of: Article Type(s), an Original Paper date range, a Retraction/Notice date range, or a PMID/DOI — a blank author-only search no longer works, a change most existing search guidance predates.

    • Author field: try name variants and the wildcard (*), e.g. *doe*, since journals list authors inconsistently.
    • Affiliation field: free text only, matched against the original journal’s wording, not a normalised list.
    • Article Type / date range: now mandatory as a search anchor; pair a rough employment period with the author name.
    • PMID or DOI: the most precise route once a specific paper is identified.

    Each search returns a maximum of 50 rows on screen, with a banner showing the true total — worth noting when a prolific or common-named candidate returns more hits than the interface displays.

    What Counts as a Genuine Red Flag Versus a False Positive?

    A retraction hit is a prompt to investigate, not a finding of misconduct. RWDB’s reason-code taxonomy (Appendix B of the user guide) separates honest error, authorship disputes and duplicate publication from deliberate fabrication — only the latter is relevant to a fitness assessment.

    Signal Likely false positive Likely genuine concern
    Author role Middle/minor co-author, no data or analysis role First, corresponding, or last author
    Reason code Honest error, journal-initiated editorial correction Data fabrication, image manipulation, plagiarism
    Pattern Single isolated retraction across a long career Multiple retractions clustered in a short period
    Notice type Correction or expression of concern only Formal retraction with a stated integrity reason

    A 2025 study via Taylor & Francis, indexed on PubMed, found metadata discrepancies between RWDB, PubMed and Web of Science for the same retracted articles — reason to cross-reference a second source before treating any record as final. RWDB also standardises the author field to “Editorial Staff” on journal-initiated notices, never to be misread as identifying the candidate.

    Paper mills add a layer: outputs typically cluster by template, image reuse or tortured phrasing across unrelated author groups, a pattern the COPE–STM Paper Mills investigation has documented since 2022. A retracted paper matching paper-mill characteristics warrants closer scrutiny than an isolated retraction.

    How Does RWDB Compare With ORI Research Misconduct Case Summaries?

    RWDB and US Office of Research Integrity (ORI) case summaries answer different questions, and due diligence needs both. RWDB tells you whether a paper was withdrawn; ORI tells you whether a person was found, after federal investigation, to have committed misconduct — even where no retraction followed.

    Feature Retraction Watch Database ORI case summaries
    Unit of record A published article/notice A named individual with a misconduct finding
    Scope Global, all disciplines and publishers US Public Health Service-funded research only
    Trigger for entry A retraction, correction, or notable EOC is published A formal ORI investigation concludes with a finding
    Typical gap Misses misconduct with no resulting retraction Misses retractions outside PHS-funded, US-linked research

    Because ORI findings can precede, follow, or occur without a retraction, checking RWDB alone misses candidates sanctioned through supervision requirements or funding debarment whose flawed papers were never withdrawn. Hiring, tenure or funding decisions should run both checks, not treat either as a substitute.

    What Does a Due-Diligence Screening Workflow Look Like in Practice?

    1. Confirm identity anchors — collect name variants, ORCID iD, and known affiliations before searching.
    2. Run the RWDB author search with a date range or article-type anchor as required, using wildcards for name variants.
    3. Filter to retractions specifically — the default result mixes in corrections and expressions of concern, which are not comprehensively indexed.
    4. Read the reason code for every hit rather than counting hits; separate honest error from fabrication, plagiarism, or image manipulation.
    5. Check ORI case summaries for the same name, independently, to catch misconduct findings with no associated retraction.
    6. Cross-reference a second metadata source (PubMed, Web of Science) before any hit informs a decision.
    7. Document the process and allow a response — record which fields were searched and on what date, and give the candidate an opportunity to explain any substantive finding before it affects the outcome.

    Answer-First Q&A on Retraction Screening

    What is the Retraction Watch Database?

    The Retraction Watch Database is a free, searchable index of scholarly retractions, corrections and expressions of concern, distributed with Crossref. It records over 65,000 retraction entries with metadata on authors, journals, dates and stated reasons — but it indexes withdrawn papers, not verified findings against individuals.

    Do retracted studies still get cited?

    Yes. Citation-tracking studies confirm retracted papers continue to be cited after the retraction notice is published, often because citing authors are unaware of it. This is one reason due-diligence checks cannot rely on citation counts as a proxy for integrity.

    What is the purpose of Retraction Watch?

    Retraction Watch exists to track and report retractions as a window into how science self-corrects, publishing the underlying blog since 2010 and the structured database since 2018. Its purpose is transparency, not adjudicating misconduct — that sits with journals, institutions, and bodies such as ORI.

    How do you check for retractions on a specific paper or author?

    Search RWDB’s author or affiliation fields, or enter the paper’s PMID or DOI directly for the most precise match. Since October 2024 the search also requires an article-type or date-range anchor, so pair an author name with an approximate publication period.

    What Are the Implications for Research Offices and Funders?

    Institutions that skip a structured check within their research administration due-diligence process risk reputational and funding harm they could otherwise catch before an offer is made. Treating a single retraction hit as automatic disqualification risks penalising honest-error corrections with no integrity finding — both failure modes are avoidable with a documented, two-source workflow.

    Authorship transparency makes this more tractable: contributor-role frameworks such as CRediT — originated by CASRAI in 2014 and now stewarded by NISO as ANSI/NISO Z39.104-2022 — let a research office consult authorship and contribution records to see whether a flagged co-author actually held a data-generating or analytical role, rather than a minor one, sharpening the false-positive filter above.

    Where Is Misconduct Screening Heading Next?

    Expect due-diligence practice to keep converging on multi-source verification rather than any single registry. As paper-mill detection tooling matures and Crossref’s stewardship of RWDB deepens, the advantage will sit with research offices that build a repeatable, documented workflow now — spanning RWDB, ORI case summaries, and contributor-role verification — rather than an ad hoc name search at the point of hire.

  • Retraction Watch Hijacked Journal Checker Guide

    The Retraction Watch Hijacked Journal Checker is a free, continuously updated public database — created by researcher Anna Abalkina in partnership with Retraction Watch — that lists confirmed cases of journal hijacking. Research offices should treat it as one input in a three-tool pre-submission workflow, alongside Think.Check.Submit and the DOAJ, rather than as a standalone verdict on a journal’s legitimacy.

    A hijacked journal is a fraudulent website that clones the title, ISSN and branding of a legitimate journal in order to solicit manuscripts and publication fees under a false identity.

    What is the Retraction Watch Hijacked Journal Checker?

    The checker began as independent detective work. Researcher Anna Abalkina uncovered overlapping, duplicated article archives while investigating plagiarism allegations, and traced the pattern back to journals whose titles, ISSNs and metadata had been copied wholesale by scam operators. Retraction Watch published the resulting resource on 29 May 2022 as a public, dynamic spreadsheet, and Nature covered its launch on 22 June 2022 under the headline “Hijacked-journal tracker helps researchers to spot scam websites”.

    By 26 December 2025, Retraction Watch reported the checker had grown to more than 400 confirmed hijacked-journal entries. It is not a static blocklist: Retraction Watch and Abalkina add titles as new hijackings are verified, and readers can submit suspected cases for investigation through a dedicated form.

    Detection relies on a repeatable analytical method rather than guesswork:

    • Comparing article archives across journals that share an identical or near-identical title
    • Spotting identical website templates reused across multiple suspect journals
    • Flagging atypical, sudden spikes in indexing volume (for example, in Scopus)
    • Identifying citations or subject matter that has no relationship to a journal’s stated scope

    How to use the checker before you submit

    The checker’s practical value sits earlier in the workflow than most guidance suggests: before a manuscript is drafted for a specific venue, not after an unsolicited invitation arrives. A research office or corresponding author should run the target journal’s exact title, ISSN and submission-site URL against the spreadsheet — hijackers frequently register a lookalike domain while keeping the legitimate journal’s name and ISSN intact, so matching on URL alone is not sufficient.

    Three checks matter most:

    • ISSN cross-reference. Confirm the ISSN printed on the target site matches the ISSN registered for that journal title, since a mismatched or duplicated ISSN is the clearest hijacking signal.
    • Domain history. Check whether the journal has recently changed domains, or whether two live websites claim the same title — a strong indicator one is a clone.
    • Scope alignment. Review a handful of recently published articles against the journal’s stated aims and scope; unrelated subject matter is a red flag the checker’s own methodology relies on.

    Because the checker only lists confirmed cases, a clean result is not proof of legitimacy — it simply means Abalkina and Retraction Watch have not yet verified a hijacking for that title. That gap is why the checker needs to sit alongside broader vetting tools rather than stand alone.

    Combining the checker with Think.Check.Submit and DOAJ

    Research offices advising authors on target-journal selection get materially better coverage by running three complementary tools in sequence, because each one screens for a different failure mode.

    Tool What it checks Best used for Key limitation
    Retraction Watch Hijacked Journal Checker Confirmed cases of title/ISSN cloning Ruling out known hijacked or cloned journals Lists only confirmed cases — absence is not proof of legitimacy
    Think.Check.Submit Publisher and journal trust signals via a structured checklist Assessing an unfamiliar journal’s overall credibility before submission A self-assessment checklist, not a verified database
    DOAJ (Directory of Open Access Journals) Open-access journals vetted against published inclusion criteria Confirming an open-access journal has passed independent editorial review Covers open-access journals only, not subscription or hybrid titles

    Think.Check.Submit is a checklist-based initiative backed by a coalition of scholarly-communication organisations, including the Committee on Publication Ethics (COPE) and DOAJ itself, and asks authors to verify a journal’s editorial board, peer-review process, and indexing claims before submitting. The DOAJ, founded in 2003, takes a different approach: it is a curated whitelist that open-access journals must actively apply to join, and inclusion signals that the journal’s editorial governance and peer-review process have already passed independent review.

    A practical sequence for a research office vetting an unfamiliar target journal:

    1. Search the exact title, ISSN and domain in the Retraction Watch Hijacked Journal Checker.
    2. Work through the Think.Check.Submit checklist for editorial transparency, peer-review claims and indexing.
    3. If the journal claims open-access status, confirm its DOAJ listing directly rather than trusting a badge displayed on the journal’s own site.
    4. Escalate anything inconclusive to your institution’s research integrity or library office before submission.

    Common questions about hijacked and predatory journals

    What is a hijacked journal?

    A hijacked journal is a fraudulent website that copies the title, ISSN and branding of a legitimate, often reputable, journal without permission. Operators use the cloned identity to solicit manuscripts and publication fees, exploiting the original journal’s reputation and indexing status to appear credible to unsuspecting authors.

    How to check cloned journals?

    Cross-check the journal’s title, ISSN and website domain against the Retraction Watch Hijacked Journal Checker, then verify the ISSN independently through an official registry. A recently changed domain, or two active websites claiming the same journal name, is a strong sign of cloning that warrants further scrutiny before submission.

    What is a red flag for a predatory journal?

    Common red flags include an unsolicited invitation promising unusually fast peer review, unclear or missing editorial board information, article processing charges that are hidden until after acceptance, and published articles whose subject matter does not match the journal’s stated scope.

    How to check if a journal is predatory?

    Run the journal through the three-tool workflow: the Retraction Watch Hijacked Journal Checker for confirmed hijacking cases, the Think.Check.Submit checklist for editorial and peer-review transparency, and DOAJ if the journal claims open-access status. No single tool is sufficient on its own.

    What this means for research offices

    Journal hijacking exploits exactly the signals institutions rely on to judge legitimacy — a familiar title, a real ISSN, and claimed indexing in databases such as Scopus. That makes it a research-integrity risk research offices should treat as distinct from generic “predatory publishing” advice, because a hijacked journal’s clone site can look more convincing than a typical low-quality predatory title.

    Embedding the Retraction Watch checker into pre-submission review — alongside Think.Check.Submit and DOAJ verification — gives research administrators a repeatable, evidence-based check rather than an ad hoc judgement call. Given the checker’s entry count has grown from launch to more than 400 confirmed cases in under four years, institutions should expect the list to keep expanding and should re-run checks for any journal an author has not published in before, even where past guidance found no match.

  • European Code of Conduct for Research Integrity: What It Says and Who Must Follow It

    The European Code of Conduct for Research Integrity is a framework for self-regulation, published by ALLEA (All European Academies), that sets out four principles — reliability, honesty, respect, and accountability — and translates them into good research practices for every scientific and scholarly discipline.

    The Code is not a law. It is a reference document: the European Commission recognises it as the standard for research integrity across Horizon Europe-funded projects, and it increasingly functions as the template that national bodies, universities, funders, and publishers draw on when they write their own rules.

    What Does the European Code of Conduct for Research Integrity Say?

    The Code was first issued in 2011 by the European Science Foundation and ALLEA, revised in 2017, and substantially updated in the 2023 Revised Edition, published on 23 June 2023. Each revision has widened its scope: the 2023 text adds provisions on open science, data management under the General Data Protection Regulation (GDPR), equity and inclusion, and — for the first time — the responsible use of generative AI in research.

    Structurally, the Code separates good research practices from research misconduct. It sets out expectations for the research environment, training and supervision, research procedures, data management, collaborative working, publication and dissemination, and reviewing, evaluating, and editing. It then defines violations — fabrication, falsification, plagiarism — and distinguishes these from lesser questionable research practices.

    Two Horizon Europe-funded initiatives illustrate how the Code operates in practice rather than as an abstract statement: the ROSiE project built its guidelines for responsible Open Science directly on the Code’s principles, and the European Research Area Forum’s living guidelines on generative AI use the same four-principle structure as their foundation.

    The Four Principles: Reliability, Honesty, Respect, Accountability

    The Code is organised around four principles, commonly abbreviated RHRA:

    • Reliability — ensuring the quality of research through sound design, methodology, analysis, and use of resources.
    • Honesty — developing, undertaking, reviewing, reporting, and communicating research transparently, fairly, and without bias.
    • Respect — for colleagues, research participants, society, ecosystems, cultural heritage, and the environment.
    • Accountability — taking responsibility for the research process, from idea to publication, its management and organisation, training, supervision, and mentoring, and its wider societal impact.

    These four principles are the load-bearing structure of the entire document: every good practice and every misconduct definition traces back to one or more of them. Institutions building their own research integrity policy typically map local commitments against RHRA rather than inventing a parallel taxonomy.

    Who Should Follow the European Code of Conduct?

    ALLEA addresses the Code to the entire research community, not to any single actor. In practice this means:

    Stakeholder Expected role under the Code
    Researchers (all career stages) Apply RHRA principles in daily research conduct, data handling, and authorship decisions
    Universities and research institutions Provide training, embed the Code in institutional policy, and investigate alleged misconduct
    Funding agencies Require compliance as a grant condition (as the European Commission does for Horizon Europe)
    Publishers and editors Apply the Code’s publication-ethics provisions during peer review and post-publication correction
    Academies and learned societies Promote the Code within discipline-specific guidance and national adaptations

    Compliance is not enforced by ALLEA itself. Enforcement sits with the institution, funder, or publisher that has adopted the Code as a condition of employment, funding, or publication — which is why national and institutional codes exist alongside it rather than instead of it.

    How the Code Relates to the Netherlands Code and the UK Concordat

    The European Code positions itself explicitly as a model, not a substitute, for national frameworks. Two of the most-cited national instruments illustrate how that works in practice.

    The Netherlands Code of Conduct for Research Integrity (Nederlandse gedragscode wetenschappelijke integriteit) was developed by the Dutch universities’ association (now Universities of the Netherlands), the Federation of Dutch University Medical Centres, KNAW, NWO, and the TO2 federation, and took effect on 1 October 2018. It uses five principles — honesty, scrupulousness, transparency, independence, and responsibility — that map closely onto RHRA but split “reliability” into scrupulousness and independence.

    The UK Concordat to Support Research Integrity, first published by Universities UK in 2012 and revised in 2019, is organised around five commitments covering rigour, transparent governance, supportive research environments, addressing misconduct, and openness. The UK Research Integrity Office (UKRIO) treats the European Code as a reference document that informs, rather than replaces, UK sector guidance.

    Framework Publisher / steward Current edition Structure Binding status
    European Code of Conduct for Research Integrity ALLEA 2023 Revised Edition 4 principles (RHRA) Non-binding; mandatory for Horizon Europe grants
    Netherlands Code of Conduct for Research Integrity Universities of the Netherlands, NFU, KNAW, NWO, TO2 2018, in force since 1 October 2018 5 principles Binding on signatory institutions
    UK Concordat to Support Research Integrity Universities UK 2019 revision 5 commitments Non-binding; signed by most UK universities

    The pattern is consistent: national codes narrow and operationalise the European Code’s four principles into locally enforceable commitments, while keeping the underlying definitions of misconduct — fabrication, falsification, plagiarism — aligned with the European text. This is also why institutions outside the EU, including in North America, Australia, and Asia, increasingly cite the European Code as a baseline reference when no comparable domestic framework exists: it offers a discipline-neutral, internationally vetted starting point rather than a jurisdiction-specific rulebook.

    Answer-First Q&A

    What Is the European Code of Research Integrity?

    The European Code of Conduct for Research Integrity is a self-regulatory framework published by ALLEA that defines good research practice across all scientific and scholarly disciplines. First issued in 2011 and most recently revised in 2023, it is recognised by the European Commission as the reference standard for Horizon Europe-funded research.

    What Are the 5 Principles of Research Integrity?

    This is a common mix-up: ALLEA’s European Code itself sets out four principles — reliability, honesty, respect, accountability — not five. The “five principles” phrasing usually refers to a national adaptation, such as the Netherlands Code of Conduct‘s five principles (honesty, scrupulousness, transparency, independence, responsibility), which subdivides the European Code’s reliability principle.

    What Are the 4 Principles of Integrity?

    Under the European Code, the four principles of integrity are reliability (sound methodology), honesty (transparent, unbiased reporting), respect (for participants, colleagues, and the environment), and accountability (responsibility across the research lifecycle). Together they form the basis for every good practice and misconduct definition in the document.

    What Are the 7 Ethical Standards in Research?

    The “seven ethical standards” typically refers to a separate human-subjects research ethics framework (associated with Emanuel et al.), covering value, scientific validity, fair subject selection, favourable risk-benefit ratio, independent review, informed consent, and respect for participants. It is distinct from — though compatible with — the European Code’s integrity-focused RHRA structure, which governs conduct rather than human-subjects protection specifically.

    Implications for Research Administrators

    For research administrators, the practical takeaway is that the European Code functions as a compliance anchor even outside its formal EU jurisdiction. Institutional research integrity policies that cite the Code’s four principles by name are easier to defend during Horizon Europe audits, easier to cross-reference against national codes, and easier to explain to international collaborators who may not recognise a purely domestic framework.

    Grant offices, integrity officers, and research administration teams reviewing or drafting institutional policy should treat the 2023 revision — not the superseded 2017 edition — as the current baseline, since the generative AI and open science provisions did not exist before 2023.

    Looking ahead, the trend toward citing the European Code as a default reference is likely to continue as more funders outside Europe adopt open science and research-integrity conditions modelled on Horizon Europe’s approach, reinforcing the Code’s role as a de facto international baseline rather than a purely regional instrument.

  • What Is Research Integrity? Principles, Not Misconduct

    What is research integrity? It is the proactive, whole-of-lifecycle commitment to honesty, rigour, transparency, care and accountability that underpins trustworthy research, from initial study design through data collection, analysis and dissemination. Research misconduct — fabrication, falsification and plagiarism — is a separate, reactive violation of these principles, not a synonym for them.

    In one sentence: research integrity is the ethical framework of honesty, rigour, transparency, care and accountability that governs how research is designed, conducted and reported, as distinct from research misconduct, which describes specific, defined breaches of that framework.

    What Does Research Integrity Actually Mean?

    Research integrity is a standard of conduct, not a compliance checkbox. The UK Research Integrity Office (UKRIO) defines it as “all of the factors that underpin good research practice and promote trust and confidence in the research process,” covering every discipline and every sector where research is carried out. The UK Committee on Research Integrity (UKCORI) puts it more simply: research has integrity “when it’s carried out in a way that is trustworthy, ethical, and responsible.”

    Crucially, integrity is proactive — a set of principles researchers, institutions, funders and publishers commit to before and during a project. Misconduct is reactive — something investigated and adjudicated only after a specific, alleged breach. Confusing the two leads institutions to treat integrity purely as a disciplinary matter, when in practice it is a culture and training issue that prevents disciplinary matters from arising at all.

    What Are the Principles of Research Integrity?

    Two internationally recognised statements define the core principles, and they do not fully overlap — a distinction most explainers skip. The Singapore Statement, agreed at the 2010 World Conference on Research Integrity, sets out four global principles. The UK Concordat to Support Research Integrity, most recently revised in 2025 according to UKRIO, sets out five UK-specific principles.

    Singapore Statement (2010, global) UK Concordat to Support Research Integrity (2025)
    Honesty in all aspects of research Honesty — in ideas, methods, data, authorship and findings
    Accountability in the conduct of research Rigour — adherence to disciplinary norms, standards and protocols
    Professional courtesy and fairness in working with others Transparency and open communication — including declared conflicts of interest
    Good stewardship of research on behalf of others Care and respect — for participants, subjects, the environment and cultural heritage
    — Accountability — individually and collectively, including to research participants

    Both frameworks converge on honesty and accountability as non-negotiable. The UK Concordat adds explicit care and respect for participants and the environment, reflecting a decade of sector-specific refinement since the Singapore Statement was first agreed.

    How Does Research Integrity Differ From Research Misconduct?

    Research integrity and research misconduct sit at opposite ends of the same continuum, but they are not mirror images — one is a standard, the other is a narrow, legally defined category of violation.

    Research integrity Research misconduct
    Proactive: a standard applied throughout the research lifecycle Reactive: investigated only after an allegation is raised
    Broad: honesty, rigour, transparency, care, accountability Narrow: fabrication, falsification, plagiarism (FFP)
    Includes honest error, disagreement and self-correction as normal science Requires intent — knowing, deliberate or reckless conduct
    Owned by researchers, institutions, funders and publishers collectively Adjudicated by institutional or national investigation panels

    The US Office of Research Integrity (ORI), which oversees Public Health Service-funded research under 42 CFR Part 93, defines misconduct as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting results. ORI’s own standard explicitly excludes “honest error or differences of opinion” — a distinction UK bodies echo when they describe transparency as permitting “humility in the process” and treating good-faith mistakes as a normal, productive part of research rather than a violation.

    Which Frameworks and Bodies Define Research Integrity in Practice?

    No single global regulator owns research integrity; instead, a small set of national and disciplinary bodies each cover part of the landscape.

    • UKRIO — the UK’s national advisory body for research integrity, providing guidance, a Code of Practice for Research, and independent case advice across all UK research sectors.
    • UKCORI — the UK Committee on Research Integrity, which monitors sector-wide trends and reports on the health of the UK’s research integrity landscape.
    • COPE (Committee on Publication Ethics) — sets guidance for journal editors and publishers on handling suspected misconduct once a manuscript or published article is implicated.
    • ORI — the US federal body enforcing 42 CFR Part 93 for Public Health Service-funded research, with formal investigation and debarment powers.

    Transparency, one of the five UK Concordat principles, has a concrete operational form: contributor-role disclosure. CASRAI originated the CRediT contributor role taxonomy in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. Declaring who did what on a paper, using a recognised taxonomy of research contributions, is one of the few integrity principles that publishers can verify mechanically rather than take on trust.

    Why Does Research Integrity Matter?

    Research integrity is the precondition for everything downstream of a study: replication, policy use, patient safety and public funding decisions all assume the underlying record is honest.

    • Public trust — health policy, technology adoption and regulatory decisions rely on the assumption that published findings reflect what was actually done.
    • Reproducibility — other researchers can only replicate and build on work that was conducted and reported rigorously in the first place.
    • Institutional and funder risk — universities and funders that cannot demonstrate a working integrity framework face reputational damage and, in the UK, scrutiny tied to Concordat compliance reporting.
    • Research administration workload — a strong integrity culture reduces the volume of formal misconduct investigations, which are costly and slow compared with upfront training and clear authorship/data policies.

    Common Questions About Research Integrity

    What are the five principles of research integrity?

    Under the UK Concordat to Support Research Integrity, the five principles are honesty, rigour, transparency and open communication, care and respect, and accountability. They apply across the whole research lifecycle, from design through dissemination, and are echoed with minor variation in the four-principle Singapore Statement.

    What is an example of research integrity?

    Per UKRIO, examples include honesty in reporting methods and procedures, accurately gathering and presenting data, correctly referencing prior work, properly acknowledging co-authors’ contributions, and making claims that are genuinely justified by the findings obtained.

    What are the four principles of the Singapore Statement?

    Agreed at the 2010 World Conference on Research Integrity, the four principles are honesty in all aspects of research, accountability in conducting research, professional courtesy and fairness in working with others, and good stewardship of research carried out on behalf of others.

    What is the core difference between research integrity and research misconduct?

    Research integrity is a proactive standard covering honesty, rigour and transparency across an entire project. Research misconduct is a narrow, reactive category — under ORI’s 42 CFR Part 93, specifically fabrication, falsification, or plagiarism — investigated only after a specific allegation is made.

    What This Means for Institutional Leaders and Early-Career Researchers

    For institutional leaders, the practical implication is sequencing: integrity training, clear authorship policies and transparent data-management requirements must sit upstream of any misconduct process, not substitute for it. A Concordat signatory institution is expected to report annually on how it embeds these principles, not merely on how many misconduct cases it has closed.

    For early-career researchers, the distinction resolves a common source of anxiety. Honest error, a null result, or a documented change of method following peer feedback is normal scientific practice under every framework reviewed here — it is not misconduct, and does not need to be disclosed defensively. What matters is transparent reporting of what was actually done.

    The Bottom Line

    Research integrity and research misconduct are frequently conflated in casual usage, but the frameworks that govern UK and international research treat them as distinct: one is a standard applied throughout a project, the other a narrow, intent-based violation investigated after the fact. Institutions that build integrity into training, authorship policy and transparent reporting — rather than treating it as a subset of misconduct procedure — see fewer formal investigations and a stronger research culture overall.

  • Is ORCID Legit? Its Limits Against Paper Mills

    ORCID is legitimate: it is a real, non-profit persistent-identifier registry used by thousands of publishers, funders and institutions worldwide. But “legitimate” is not the same as “fraud-proof.” ORCID’s own documentation confirms that an ORCID iD verifies control of an email address and account — not a researcher’s real-world identity, credentials, or institutional affiliation — which is exactly the gap paper mills exploit.

    An ORCID iD is a free, sixteen-digit persistent identifier that distinguishes one researcher from another and links that person to their publications, grants and affiliations. That single-sentence definition explains why ORCID is trusted — and why, on its own, it was never designed to stop organised authorship fraud.

    This piece is a CASRAI editorial perspective: it argues that identity-layer tools like ORCID and contribution-layer tools like the CRediT taxonomy solve different problems, and that conflating the two leaves a detection gap that paper mills are actively exploiting.

    Contents

    What does an ORCID iD actually verify?

    An ORCID iD confirms that a person controls a given ORCID account and email address, and it links that account to a persistent, disambiguated researcher record. It does not independently confirm a person’s legal identity, employment, qualifications, or that they actually authored the works attached to their profile.

    ORCID’s own guidance is explicit on this point: the organisation states that an ORCID iD is not a form of identity verification in the government-ID sense. Registration requires only a working email address, which is the same low bar that lets a legitimate early-career researcher register in seconds — and lets a paper mill spin up a disposable account just as fast.

    Is ORCID legit? The non-profit case

    Yes. ORCID is a genuine, mission-driven non-profit — ORCID is a global, not-for-profit organisation sustained by member fees from universities, publishers and funders, not by selling researcher data. It is embedded in submission workflows at major publishers and grant systems precisely because it solved a real problem: name ambiguity.

    • Common-surname collisions are severe — a mere hundred surnames account for over 85% of China’s population, with Wang, Li and Zhang alone covering more than a fifth, making name-only attribution unreliable at scale.
    • ORCID lets a researcher control which affiliations, works and peer-review activity are publicly visible, rather than relying on a publisher’s guesswork.
    • Adoption is now effectively mandatory at many funders and journals, which is a trust signal in itself — but mandated use is not the same as verified authenticity.

    So the trust question and the fraud-detection question are separate. ORCID earns trust as infrastructure; it was never marketed, and does not function, as an authorship-fraud filter.

    Can identity verification stop paper-mill authorship rings?

    No — not on its own, and the evidence for that is now substantial. The Committee on Publication Ethics (COPE) and the STM Association jointly defined and characterised the problem in their December 2022 Paper Mills Research Report, describing paper mills as commercial operations that manufacture fabricated or manipulated manuscripts and sell authorship slots, often to researchers under career pressure to publish.

    The scale became undeniable in the retraction data. Publishers retracted more than 10,000 research papers in 2023 — a record documented by Nature’s news team, with a large share traced to paper-mill-linked special issues, concentrated heavily at a single Wiley/Hindawi imprint before its special-issue programme was shut down. An ORCID iD attached to a fabricated paper did not prevent a single one of those retractions; in many cases the fraudulent authors held valid, active ORCID accounts throughout.

    That is the structural weakness: paper mills do not need to defeat ORCID, they only need to open an account, which requires nothing more than an email inbox. Publishers in response formed the STM Integrity Hub, launched in 2022, a shared cross-publisher infrastructure that pools signals — duplicate submissions, manipulated peer-review rings, image and reference manipulation — across member publishers in something ORCID’s single-account model cannot replicate, because ORCID has no mandate or mechanism to police manuscript content.

    Why a contribution taxonomy like CRediT tackles a different problem

    Identity tools answer “who is this person?” Contribution taxonomies answer a different, equally necessary question: “what did this specific person actually do on this specific paper?” CRediT, the contributor role taxonomy, was originated by CASRAI in 2014 and is now stewarded by NISO as ANSI/NISO Z39.104-2022 — CASRAI is the originator, not the current standards steward.

    CRediT requires each listed author to be tagged against a defined set of contributor roles — conceptualisation, data curation, formal analysis, writing, and others — for every submitted manuscript. That disclosure layer creates a different fraud signal than identity ever could: a co-authorship pattern where a name appears solely under “funding acquisition” across dozens of unrelated papers in a short window is implausible in a way that a valid ORCID iD alone will never flag, because ORCID has no visibility into role-level contribution claims.

    Neither tool substitutes for the other. Identity infrastructure and contribution disclosure address separate failure modes, and a detection strategy that leans on only one is structurally incomplete.

    Tool What it verifies or standardises What it does not do
    ORCID iD Persistent identifier; confirms control of an account/email and disambiguates a researcher’s name across works Does not verify legal identity, institutional affiliation or credentials
    CRediT taxonomy (ANSI/NISO Z39.104-2022) Standardises disclosure of which of the defined contributor roles each named author performed Does not verify that the named person exists, consented, or was even contacted
    STM Integrity Hub Shares cross-publisher fraud signals in real time — duplicate submissions, manipulated peer review, image reuse Does not itself confirm any individual author’s identity

    Answer-first Q&A

    Is ORCID legitimate?

    Yes. ORCID is a genuine, non-profit registry that provides persistent researcher identifiers and is integrated into submission systems at most major publishers and funders. Legitimacy as an organisation, however, is separate from its capacity to verify identity — ORCID confirms account control, not real-world credentials.

    Is it safe to share an ORCID iD?

    Yes. An ORCID iD is a public, non-sensitive identifier by design, and researchers control visibility settings for the underlying record. Sharing it on a CV, manuscript, or grant application does not expose private data, since ORCID does not store the kind of personal information used for identity theft.

    Should you use ORCID?

    Yes, for disambiguation and administrative efficiency. An ORCID iD saves time on grant and manuscript forms and reliably links a researcher’s outputs across name changes or institutional moves. It should not, however, be treated by editors or reviewers as evidence that a submission’s authorship is authentic.

    Is ORCID credible?

    Yes, as infrastructure. ORCID is a trusted, community-governed non-profit that cannot be bought by a commercial entity and does not sell researcher data. Credibility as a registry does not, however, extend to guaranteeing the integrity of any individual manuscript that cites an ORCID iD.

    Implications for publishers, institutions and funders

    Editorial offices that treat a valid ORCID iD as a clearance signal are relying on infrastructure built for a different job. A layered approach performs better:

    • Require CRediT contributor-role statements alongside ORCID iDs, so implausible role patterns become visible at submission, not after retraction.
    • Cross-check institutional email domains and affiliations, since paper mills routinely fabricate both.
    • Join or query shared infrastructure such as the STM Integrity Hub, which pools cross-publisher fraud signals ORCID was never designed to hold.
    • Treat ORCID account age and activity history as a weak signal only — a freshly created account attached to a first submission warrants closer editorial scrutiny, not automatic rejection.

    Conclusion: identity plus contribution, not identity alone

    ORCID is legitimate infrastructure doing exactly the job it was built for: disambiguating researcher identity across a fragmented publishing ecosystem. Expecting it to also police fabricated authorship asks a registry to perform forensic work it has no data or mandate to do. COPE and STM’s own analysis, and the 2023 retraction record, both point the same direction: stopping paper mills requires layered defences — identity infrastructure, authorship policy, contribution disclosure, and shared publisher intelligence — working together, because no single layer was designed to catch what the others miss.

  • Guest Authorship: Why CRediT Alone Fails

    Guest authorship occurs when a research paper’s byline, or its CRediT contributor statement, names someone who did not perform the work described. Because CRediT statements are self-reported by the corresponding author with no independent check, they can record a false contribution as easily as a true one — the taxonomy documents intent, not proof.

    Guest authorship is the practice of crediting an individual — typically an influential or senior figure — as an author or contributor on a study they did not substantively perform, in order to lend the paper credibility or satisfy a hierarchy. It sits alongside gift authorship (crediting a colleague as a favour) and ghost authorship (omitting someone who did the work), and all three predate CRediT by decades. The open question is whether a standardised contributor-role taxonomy actually closes the loophole, or simply gives guest authorship a more official-looking form to hide behind.

    What counts as guest authorship?

    The International Committee of Medical Journal Editors (ICMJE) sets four cumulative criteria for authorship: substantial contribution to the work’s conception or data; drafting or critical revision; final approval of the version published; and agreement to be accountable for it. A guest author fails at least the first criterion — and often all four — yet appears on the byline regardless.

    The Committee on Publication Ethics (COPE) defines a guest author as someone “added, with or without their knowledge, to make the author list look more impressive despite having no involvement with the research.” COPE’s authorship flowchart, last updated in 2024, groups guest authorship with gift and coercive authorship as related but distinct forms of the same underlying problem: a byline that does not reflect who actually did the work.

    Guest, gift and ghost authorship compared

    These terms are frequently used interchangeably, but the mechanism and the harm differ in each case.

    Practice What happens Typical driver CRediT interaction
    Guest authorship An influential outsider is named as author for prestige, with no involvement in the study Boosting perceived credibility or acceptance odds Roles are invented and attached retroactively to justify the byline
    Gift authorship A colleague, mentor or junior researcher is credited as a favour or reward Reciprocity, career support, maintaining relationships Minor or symbolic roles (e.g. “supervision”) are assigned regardless of actual input
    Coercive authorship A senior figure insists on inclusion because they run the lab or hold the funding Power imbalance between principal investigator and juniors The senior author dictates their own — and sometimes others’ — declared roles
    Ghost authorship Someone who did substantial work (often a medical writer) is omitted entirely Commercial sponsors wanting distance from the publication The omitted contributor’s real role never appears in the statement at all

    Why self-declared CRediT statements don’t stop it

    CASRAI originated the CRediT contributor role taxonomy in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. It gives editors and readers 14 defined roles — from Conceptualization to Writing – Original Draft — in place of an undifferentiated author list. That is a genuine improvement in transparency. It is not, on its own, a verification system.

    Three structural gaps explain why:

    • No independent attestation. The corresponding author typically submits the entire CRediT statement on behalf of every co-author. Most journal workflows do not require each named contributor to individually confirm their assigned roles before publication.
    • No cross-check against evidence. A “Formal analysis” or “Investigation” tag is accepted as declared; journals do not routinely request lab notebooks, data-access logs or version-control history to substantiate it.
    • Power dynamics survive the paperwork. A principal investigator who insists on inclusion can equally insist on which role is recorded against their name. The taxonomy formalises the description of a contribution; it cannot compel the description to be honest.

    The scale of the underlying problem predates CRediT and has persisted through its adoption. A 2011 BMJ cross-sectional survey by Wislar and colleagues, examining high-impact medical journals that already required contributorship disclosure, found honorary authorship in 21% of sampled research articles — direct evidence that a disclosure requirement, by itself, does not eliminate the practice it is meant to surface. Ghostwriting scandals tell the same story from the other direction: the withdrawal of the diet drug dexfenfluramine (Redux) from the US market in 1997, after reports linking it to cardiac valve injury, followed years in which academic names had been attached to industry-drafted manuscripts on the drug’s safety — a pattern documented in subsequent publication-ethics literature on pharmaceutical ghostwriting.

    What would actually close the gap

    Closing the gap requires moving verification outside the self-reporting author group. Several mechanisms already exist in partial form and could be combined into a working check.

    • ORCID-linked contributor confirmation. ORCID iDs already let researchers verify affiliations and works against institutional records. Requiring each co-author to confirm their own CRediT roles via their ORCID account — rather than accepting a single submission from the corresponding author — would close the “submitted on your behalf” loophole.
    • Editor-level plausibility checks. COPE’s flowchart already lists warning signs — implausibly long author lists, late additions, unresponsive co-authors — that editorial staff can screen for before acceptance, without new infrastructure.
    • Publisher-side integrity screening. Cross-publisher initiatives such as the STM Integrity Hub, run by the International Association of STM Publishers, pool signals across journals to flag manuscripts and author patterns associated with paper mills and authorship manipulation, extending scrutiny beyond what any single journal can see alone.
    • Institutional sign-off at submission. Some research offices now require every named author to countersign the submitted contributor statement before a manuscript leaves the institution — shifting the accountability point upstream of the journal entirely.

    None of these is sufficient alone. Combined, they replace a single self-declared statement with several independent points where a false claim can be caught before publication rather than after retraction.

    Answer-first Q&A

    What is a guest authorship?

    Guest authorship is when an individual is named as an author or contributor on a research paper despite having made no substantive intellectual or practical contribution to the study. The name is typically added to lend prestige, improve perceived credibility with reviewers, or satisfy an informal hierarchy inside a research group.

    What is honorary guest authorship?

    Honorary guest authorship describes the same practice as gift authorship: crediting a senior or well-known researcher — often a department head or supervisor — who provided general oversight or facilities but did not meet formal authorship criteria such as those set by the ICMJE. It is one of the most commonly reported forms of authorship misconduct.

    What are the four problematic types of authorship?

    Publication-ethics literature groups authorship misconduct into guest, gift, coercive and ghost authorship. Guest and gift authorship credit someone who did not contribute; coercive authorship results from a power imbalance forcing inclusion; ghost authorship is the reverse — omitting a genuine contributor, often a paid medical writer, from the byline entirely.

    What does authorship mean?

    Under ICMJE criteria, authorship requires substantial contribution to a work’s conception or data, drafting or critical revision of the manuscript, final approval of the published version, and accountability for the work’s accuracy and integrity. All four conditions must be met; meeting only one does not qualify a contributor for the byline.

    Implications for editors, institutions and funders

    For editors, the practical implication is that a CRediT statement should be treated as a starting point for scrutiny, not a closing one. Plausibility checks already recommended by COPE cost nothing to implement and catch the crudest cases — implausible author counts, contributions that don’t match a co-author’s known expertise, late-stage additions to the byline.

    For institutions and funders, the implication is upstream: research integrity offices and grant terms can require ORCID-verified, individually confirmed contributor statements as a condition of institutional co-authorship or funding acknowledgement, rather than leaving verification entirely to journals with limited capacity to investigate.

    For developers building submission systems, the opportunity is to make individual confirmation the default workflow rather than an opt-in extra — turning a document that records one person’s account into one every named party must attest to.

    CRediT made contributorship visible. Making it verifiable is the unfinished half of the same reform, and it will require identity infrastructure and editorial process — not a taxonomy update — to complete.

  • Research Misconduct Policy: Lehigh’s 2026 Update Sets the Pace for Peer Institutions

    A research misconduct policy is the institutional and federal framework that defines fabrication, falsification, and plagiarism (FFP) in research, and sets out how allegations are reported, investigated, and adjudicated. Lehigh University’s new research misconduct policy took effect on 1 January 2026, and it is not an isolated update: dozens of US research universities revised their policies for the same date, all responding to the first substantial rewrite of the federal research misconduct rule in two decades.

    Research misconduct policy in the United States is not institutional discretion. Any university receiving Public Health Service (PHS) funding — the great majority of federally funded research institutions — must maintain a policy satisfying 42 CFR Part 93, administered by the HHS Office of Research Integrity (ORI). When that regulation changes, every covered institution’s policy changes with it. That happened in 2024, and 1 January 2026 is when the consequences arrived on campus.

    What does Lehigh’s new research misconduct policy change?

    Lehigh’s Office of Research Integrity finalised its revised policy on 19 December 2025, in a notice from Naomi E. Coll, Director of Research Policy and Compliance, confirming that the policy would take effect on 1 January 2026. The document sets out how the university assesses, inquires into, and investigates allegations of research misconduct against academic, scientific, and professional staff, students, and contractors, regardless of funding source.

    What distinguishes Lehigh’s process is its provenance rather than its content: the policy was drafted by a faculty working group with one representative from each college, presented to the Faculty Senate in November 2025, and opened to a university-wide online public comment period before finalisation. That sequence — draft, Senate review, public comment, publication — is now a template other institutions are following as they race the same federal deadline.

    What is the federal research misconduct policy institutions must follow?

    The federal research misconduct policy originates with the Office of Science and Technology Policy’s 2000 Federal Policy on Research Misconduct and is codified for PHS-funded research at 42 CFR Part 93. It defines research misconduct as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results — honest error and honest differences of opinion are explicitly excluded.

    A formal finding requires three elements together: a significant departure from accepted practices of the relevant research community, conduct that was intentional, knowing, or reckless, and proof by a preponderance of the evidence. Non-PHS agencies apply parallel rules — the National Science Foundation administers its own version at 45 CFR Part 689 — so multi-funder institutions must reconcile more than one regulatory text in a single policy.

    What changed in the 2024 ORI Final Rule (42 CFR Part 93)?

    ORI published its final rule in the Federal Register on 17 September 2024 — the first substantive revision to the 2005 regulation. The rule became legally effective on 1 January 2025, but institutions only had to apply it to allegations received on or after 1 January 2026, which is why the current wave of policy rewrites is landing now rather than a year ago.

    • Defined intent standard: “Intentionally,” “knowingly,” and “recklessly” — previously undefined terms central to any finding — now carry fixed regulatory definitions.
    • New “institutional record” definition: the rule specifies, for the first time, exactly which documents (inquiry and investigation reports, sequestered evidence indexes, appeal records) must be compiled and preserved.
    • Seven-year retention rule: institutions must secure the institutional record and all sequestered evidence for seven years after the proceeding — or any related HHS proceeding — concludes, whichever is later.
    • Longer inquiry window: the initial inquiry phase is extended from 60 to 90 days, giving Research Integrity Officers more time before deciding whether a full investigation is warranted.

    ORI has confirmed it will not require institutions to submit revised policies until the annual report covering 2025 is filed, due by 30 April 2026 — but the policies themselves, and the procedures behind them, must already be in force for any allegation received from 1 January 2026 onward.

    Which other universities are revising policies for 2026?

    Lehigh is one of a cohort. Institutional policy pages and faculty handbooks show a cluster of revisions timed to the same compliance date, though each institution has followed its own governance path to get there.

    Institution Policy action Date Notes
    Lehigh University New research misconduct policy finalised Effective 1 Jan 2026 Faculty working group, Senate review, public comment
    Columbia University Revised policy approved by University Senate Approved 12 Dec 2025; effective 1 Jan 2026 Realigns definitions with the PHS Final Rule
    Auburn University Policy on Research Misconduct republished 21 Nov 2025 Updated allegation-resolution framework
    Ohio State University Research Misconduct policy revised March 2025 Among the earliest movers ahead of the deadline
    Wayne State University Interim Research Misconduct Policy (26-01) Interim, 2025–26 cycle Document numbering signals the 2026 compliance cycle
    Duke University Misconduct in Research policy (established) Bound to 42 CFR Part 93 / 45 CFR Part 689 Long-cited model policy; must reflect the revised rule by the deadline

    The pattern is consistent: governance bodies — Faculty Senate, University Senate, or equivalent — are being used explicitly to legitimise the revision, not just administrative sign-off. That marks a shift from prior cycles, where research misconduct policy updates were typically handled as compliance housekeeping rather than faculty-governance business.

    Common questions on research misconduct policy

    What are the three forms of research misconduct under US federal policy?

    US federal policy recognises three forms of research misconduct: fabrication (making up data or results), falsification (manipulating materials, equipment, or data so the research record is inaccurate), and plagiarism (appropriating another person’s ideas, processes, results, or words without credit). This “FFP” definition has applied since the 2000 OSTP policy and is unchanged by the 2026 rule.

    What is considered research misconduct in the US?

    Conduct only counts as research misconduct if it is a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, and proven by a preponderance of the evidence. Honest error, differences of scientific opinion, and most authorship disputes are explicitly excluded from the definition.

    What is 42 CFR Part 93?

    42 CFR Part 93 is the codified federal regulation — the Public Health Service Policies on Research Misconduct — that sets binding rules for how PHS-funded institutions must respond to allegations. Its 2024 revision, effective for allegations from 1 January 2026, is the first major overhaul since 2005 and drives the current round of university policy rewrites.

    What does the federal research misconduct policy cover?

    The federal research misconduct policy covers federally funded research and funding proposals across all fields — including medicine, social sciences, engineering, and statistics — conducted at universities, federal laboratories, and other funded research institutions. It governs the inquiry, investigation, and adjudication phases but does not supersede separate rules on human-subjects protection, animal welfare, or financial conflicts of interest.

    What this means for research administrators

    The consequences of research misconduct under the federal framework range from correction of the research record and letters of reprimand to suspension of funding, debarment from future federal awards, and referral for civil or criminal fraud proceedings. For research administrators, the sharper immediate risk is procedural: if an institution’s inquiry, evidentiary, or retention procedures do not match the 2026 rule, findings made under a defective process are vulnerable on appeal.

    Three takeaways follow. First, Research Integrity Officers should confirm their policy explicitly defines “intentionally,” “knowingly,” and “recklessly” in the regulatory terms now fixed by the final rule, rather than leaving them undefined as most pre-2026 policies did. Second, retention schedules need extending to the mandated seven years and mapped against the newly defined “institutional record.” Third, institutions routing revisions through faculty governance — as Lehigh, Columbia, and Auburn have done — are building a stronger due-process record that may matter if a finding is later contested.

    The compliance clock does not stop at 1 January. ORI’s own review of revised policies, via the annual report covering 2025, falls due on 30 April 2026 — a second checkpoint on which institutions treated this as a genuine revision to research administration practice, and which merely updated a document to survive it.

  • Duplicate Publication vs. Salami Slicing: A COPE Guide for Editors

    Duplicate publication is the republication of substantially the same data, analysis or conclusions in more than one paper without full disclosure and cross-referencing to the original. Splitting one dataset into several papers is legitimate only when each paper answers a genuinely distinct question, adds a new contribution, and is fully disclosed to every editor involved — anything less risks being classed as salami slicing or redundant publication under COPE guidance.

    Duplicate publication is one of the most common editorial integrity problems editors encounter. The Committee on Publication Ethics (COPE) treats it, alongside “salami slicing” (dividing one study into the smallest publishable units), as a form of redundant publication that misleads readers and wastes peer-review capacity. This guide uses COPE’s own case guidance to show exactly where the line sits between a legitimate multi-paper research programme and a compliance breach.

    Contents

    What is duplicate publication and how does it differ from salami slicing?

    Duplicate (or redundant) publication is the submission or publication of a paper that overlaps substantially — in hypothesis, data, methods, results or conclusions — with a paper already published, without acknowledging or citing the earlier work. The COPE case archive documents this pattern repeatedly: two journals independently publish near-identical articles from the same author group, unaware of each other, because the overlap was not disclosed at submission.

    Salami slicing is related but distinct: instead of publishing the same paper twice, authors divide one coherent study into the smallest set of “publishable units”. Neither practice is automatically dishonest at the point of writing; both become misconduct at the point of non-disclosure. The ICMJE Recommendations (updated January 2024) state that authors must not submit “papers describing essentially the same content to more than one journal” and must disclose all related submissions from the same dataset at the point of submission.

    When is splitting one dataset into multiple papers legitimate?

    Partial publication in research is not, by itself, unethical. Large studies — multi-site trials, longitudinal cohorts, complex mixed-methods programmes — routinely generate more than one legitimate paper. The test COPE and ICMJE apply is whether each paper stands alone as a distinct, substantial contribution, not whether the data originate from a single collection exercise.

    A split is defensible when the following conditions hold:

    • Each paper addresses a separate, pre-specified research question with its own hypothesis, analysis plan and conclusion — not a restatement with a slightly different subgroup.
    • Each paper makes a substantial, non-overlapping contribution, so a reader needs both papers to understand the full programme, but neither is redundant alone.
    • Authors disclose all related and prior submissions to every editor involved, including manuscripts under review elsewhere from the same dataset.
    • Papers are explicitly cross-referenced, so readers and systematic reviewers can identify the shared dataset and avoid double-counting participants.
    • Any secondary or translated publication follows the ICMJE’s conditions for acceptable secondary publication — both journals’ editors informed, primary publication respected, and readers told via a footnote.

    A cohort study reporting baseline characteristics in one paper and a distinct clinical outcome analysis eighteen months later is typically legitimate partial publication. A single trial reported twice with the discussion reworded is not — this is what duplicate publication bias in evidence synthesis refers to: the same result counted twice in a meta-analysis because the overlap went undetected.

    What do COPE case studies show about editorial decisions?

    COPE’s published case discussions are instructive because they show how editors reason through ambiguous, real submissions rather than textbook definitions. In one widely cited case, a newly appointed editor noticed that an article just published in their journal closely resembled one published months earlier elsewhere by the same author group (with two additional names added). The later paper reported a subset of the earlier paper’s results, and both reached an identical conclusion.

    The authors explained that the first paper reported “preliminary findings” and the second “final results based on a larger dataset” — an explanation COPE Council members treated with scepticism. Their advice highlighted several markers editors should weigh:

    Marker What it suggests
    Sentences rearranged but conclusions identical Deliberate reworking rather than genuine reanalysis
    All authors signed copyright forms without flagging overlap Plausible but unlikely genuine oversight
    Same conclusion drawn from an overlapping subset No new substantial contribution — redundant, not partial
    Neither editor informed of the other submission Breach of the disclosure obligation, regardless of intent

    The outcome was a jointly published notice of inadvertent duplicate publication in both journals — a remedy COPE’s redundant (duplicate) publication flowchart sets out for a confirmed post-publication overlap. Where overlap is caught at submission instead, COPE’s parallel flowchart directs editors to seek explanation from the authors before deciding to accept, reject, or request the manuscripts be combined.

    What should editors and authors check before publication?

    Editors handling a manuscript that may derive from a previously used dataset should not rely on author self-declaration alone. A structured check reduces both false accusations and missed cases:

    • Ask authors directly, at submission, whether any part of the data, cohort or findings has appeared in — or been submitted to — another publication.
    • Compare the introduction, methods and conclusion sections for substantive overlap, not just the abstract.
    • Check whether the “new” paper’s conclusion could reasonably have been drawn from the earlier paper alone.
    • Confirm that any secondary or translated publication meets the ICMJE’s disclosure and footnote conditions.
    • Ask authors to state, in the cover letter, how this submission differs from and complements other linked outputs.

    Clear, role-specific contributorship statements also help editors assess legitimacy quickly: where different authors led different analyses within a shared dataset, a structured contributor role taxonomy such as CRediT makes it easier to see that a paper’s intellectual contribution is genuinely distinct rather than a relabelled version of prior work. CASRAI originated the CRediT contributor role taxonomy in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022. Journals that also require full authorship criteria disclosure alongside dataset provenance statements catch most cases before peer review.

    Answer-first Q&A on duplicate publication

    What is a duplicate publication?

    A duplicate publication is a paper that overlaps substantially — in hypothesis, data, methods, results or conclusions — with an article already published, submitted without disclosing that overlap. It differs from legitimate secondary publication because the earlier work is not acknowledged or cross-referenced.

    What is the difference between redundant publication and duplicate publication?

    Redundant publication is the broader category, covering any republication of substantially the same material, including salami slicing. Duplicate publication is the specific case where two papers are near-identical in content — the narrowest and most serious form of redundancy.

    What is a dual publication?

    “Dual publication” is a synonym for duplicate publication: the same article, or one overlapping substantially with it, published in two separate journals without acknowledgement of the first. It is treated identically under COPE and ICMJE guidance regardless of which term is used.

    What should an editor do if duplicate publication is suspected?

    Editors should follow COPE’s published flowcharts: for a submitted manuscript, seek an explanation from the authors before deciding to accept, reject or request combination into a single paper; for an already-published article, contact both journals’ editors, review the extent of overlap, and issue a joint notice or correction as warranted.

    Implications for multi-paper research programmes

    For research administrators overseeing large, multi-output programmes, the practical implication is procedural: build dataset-provenance disclosure into submission workflows before manuscripts reach a journal, not after a reviewer flags overlap. Funders and institutions increasingly expect research offices to demonstrate that outputs from a shared dataset are distinct contributions, not salami-sliced units inflating a publication count.

    Analyses of retraction reasons catalogued in the Retraction Watch Database consistently place duplication among the recurring categories behind retraction notices, alongside plagiarism and data-integrity concerns — a reminder that the cost of getting this wrong is a permanent mark on the published record, not merely a desk rejection. As multi-site and multi-arm studies become more common, editors and authors who apply COPE’s disclosure-first standard consistently, rather than relying on ad hoc judgement calls, are best placed to keep legitimate partial publication distinct from redundant publication.

  • Research Misconduct NHS: How Governance Differs from University Policy

    Research misconduct NHS allegations are not resolved as a purely internal university disciplinary matter. Because a designated research sponsor and the Health Research Authority (HRA) hold formal accountability under the UK Policy Framework for Health and Social Care Research, misconduct in NHS-hosted clinical studies routes through trust-level research governance and, for doctors, potential General Medical Council scrutiny — running alongside, not instead of, any university process.

    Research misconduct is behaviour that deliberately or recklessly falls short of the standards expected in the conduct of research, spanning fabrication, falsification, plagiarism, and breaches of the ethical or regulatory approvals a study depends on.

    What Counts as Research Misconduct in NHS-Hosted Research?

    In an NHS setting, research misconduct covers the same core categories recognised across UK research generally, but with an added patient-safety dimension. Proceeding without the ethics approval, HRA Approval, or informed consent a study requires is treated as seriously as fabricating data.

    • Fabrication or falsification of results, including patient consent records
    • Plagiarism of ideas, protocols, or published text
    • Undeclared conflicts of interest affecting clinical decision-making
    • Conducting research without the required ethical or regulatory permissions in place
    • Deviating from an approved protocol without reporting the change

    The UK Research Integrity Office (UKRIO) frames this as behaviour that “deliberately or recklessly” falls short of expected standards — a threshold that separates genuine misconduct from honest error, which most NHS trust policies classify instead as a “questionable research practice” requiring correction rather than disciplinary action.

    Who Investigates? The Sponsor, the HRA and Trust Governance

    The pivotal difference from a university-only inquiry is the statutory concept of the research sponsor. Under the UK Policy Framework for Health and Social Care Research (Health Research Authority and the four UK health departments, first published 2017), the sponsor — usually the NHS trust, a university, or a commercial entity — takes on legal responsibility for confirming a study’s initial and ongoing suitability.

    This changes who is notified and when:

    • The NHS trust’s Research and Development (R&D) office, or the trust’s Director of Research, typically leads the initial assessment of an allegation raised on trust premises
    • Serious breaches of Good Clinical Practice or the approved protocol in a clinical trial must be reported by the sponsor to the HRA (and, for medicines trials, the MHRA) within statutory timeframes — a duty that has no direct equivalent in a purely observational university study
    • The relevant NHS Research Ethics Committee must be informed where the breach affects participant safety or the ethical basis of the study
    • Where fraud is suspected, the NHS Counter Fraud Authority can be engaged in parallel to any research-integrity investigation
    • For registered doctors, nurses, or other regulated professionals, a finding of misconduct can trigger a separate referral to the General Medical Council or equivalent professional regulator, independent of the employer’s own outcome

    UKRIO’s model procedure — the template most university codes of practice are built on — is advisory rather than statutory. NHS research governance, by contrast, sits inside a framework with mandatory reporting duties attached to the sponsor role, which is why an allegation in an NHS-hosted trial can trigger regulatory notifications a university-only investigation would never generate.

    NHS Research Misconduct vs University Procedures: Where They Diverge

    Both systems share the same underlying commitments — the Concordat to Support Research Integrity (Universities UK, 2019) and UKRIO’s guidance inform both — but the accountable parties and mandatory notifications differ sharply.

    Dimension University-led research NHS-hosted clinical research
    Primary framework Concordat to Support Research Integrity (Universities UK, 2019) UK Policy Framework for Health and Social Care Research (HRA, 2017)
    Accountable party The employing institution’s “Named Person” / Responsible Officer The research sponsor, working with the host trust’s R&D office
    Investigating body Institutional panel, often with external academic peers Trust governance process, informed by sponsor obligations to the HRA
    Mandatory external notification Rare — typically only funders or journals if the record needs correcting HRA/MHRA for serious breaches; REC for participant-safety issues; Counter Fraud Authority where fraud is suspected
    Professional regulator exposure Uncommon unless a professional body membership is engaged Possible GMC, NMC or equivalent fitness-to-practise referral for regulated clinicians
    Guiding non-statutory body UKRIO model procedure UKRIO guidance, applied within HRA sponsor obligations

    The practical effect: an NHS-hosted allegation can generate two or more concurrent processes — sponsor/trust governance and, if a professional regulator becomes involved, a fitness-to-practise track — whereas a university-only case usually resolves within a single institutional procedure.

    What Dual-Employment Researchers Need to Know

    Most clinical academics hold a substantive university post alongside an honorary research contract or “letter of access” with an NHS trust, arranged through the NHS Research Passport system. This dual status means an allegation can, in principle, be picked up by either employer’s procedure — or both.

    • Establish early which organisation is the study’s sponsor: sponsor obligations under the UK Policy Framework sit with that entity, not automatically with the employer
    • Expect the university and the NHS trust to agree a lead institution for the investigation, informed by UKRIO’s guidance on cross-institutional cooperation, with the second body kept informed rather than running a parallel duplicate inquiry
    • Understand that an honorary contract does not exempt a researcher from either institution’s disciplinary powers — sanctions (suspension of research privileges, restriction of clinical duties, dismissal) can be applied independently by each party
    • Keep records of ethical approvals, protocol versions, and consent documentation accessible to both employers, since a trust R&D office and a university research office may request the same evidence separately

    Research administrators supporting joint appointments should confirm, before a study opens, which institution’s misconduct procedure will apply if a concern is raised — this sits alongside the wider governance responsibilities covered under research administration frameworks.

    Frequently Asked Questions

    What is an example of misconduct in the NHS?

    In an NHS research context, a documented example is proceeding with a clinical trial without valid ethics approval or falsifying patient consent records. Both breach the UK Policy Framework for Health and Social Care Research and trigger sponsor reporting duties to the Health Research Authority, independent of any wider workplace conduct issue.

    What are the three types of research misconduct?

    The three most widely recognised categories are fabrication (inventing data or results), falsification (manipulating data, materials, or processes to misrepresent findings), and plagiarism (using others’ work or ideas without acknowledgement). UK bodies including UKRIO also recognise a broader “questionable research practices” category for less severe lapses.

    What is considered the most serious form of research misconduct?

    Fabrication of results or consent data is generally treated as the most serious category, because it directly corrupts the evidence base and, in clinical research, can endanger patient safety. In NHS-hosted studies, fabrication findings typically prompt both sponsor notification to the HRA and professional regulator referral for the individual involved.

    What is a sackable offence in NHS?

    A confirmed finding of fabrication or falsification in NHS-hosted research is normally treated as gross misconduct and can constitute a sackable offence under trust disciplinary policy. For registered clinicians, the same finding can additionally trigger a General Medical Council fitness-to-practise referral, separate from the employer’s own decision.

    The structural distinction matters beyond individual cases. As more clinical trials run through joint university–NHS sponsorship arrangements, institutions that treat research governance as a single, unified track — rather than mapping sponsor, trust, and employer obligations separately — risk missing mandatory notifications the UK Policy Framework requires. Clear, pre-agreed lead-institution protocols for dual-employment researchers remain the most effective safeguard.

  • Corrigendum vs Erratum: A Decision Framework

    A corrigendum corrects an error the authors introduced before publication — flawed data, a wrong affiliation, a miscalculation — while an erratum corrects an error the publisher introduced during production, such as a typesetting mistake or a misplaced figure. A retraction withdraws the paper entirely because its findings can no longer be trusted. Which notice an editor issues depends on who caused the error and whether it invalidates the paper’s conclusions.

    A corrigendum vs erratum decision is one of the most common — and most frequently mishandled — calls a journal editor or research integrity office makes. Get it wrong and a paper that needed only a correction ends up stigmatised as retracted, or worse, a paper with compromised findings survives under a cosmetic “correction” label. This explainer sets out a COPE-aligned decision framework for distinguishing corrigenda, errata, and retractions, and for knowing when an interim Expression of Concern is the right holding step.

    Definition: a corrigendum is a post-publication notice correcting an error the authors introduced into an already-published article, distinct from an erratum, which corrects an error the journal or publisher introduced during production.

    Contents

    What Is the Difference Between a Corrigendum and an Erratum?

    The Committee on Publication Ethics (COPE) states the working distinction plainly: “the term erratum usually refers to a production error, caused by the journal,” while “the term corrigendum (or correction) usually refers to an author error.” An erratum fixes something the journal’s own production process broke — a dropped decimal point during typesetting, a caption swapped between two figures, an author’s name misspelled by a copyeditor. A corrigendum fixes something wrong in the manuscript the authors submitted — an incorrect data table, a miscalculated statistic, an omitted funding disclosure, a wrong affiliation.

    Both notices share one condition: the underlying conclusions of the paper must remain valid. Neither is a vehicle for revising results, adding new data, or reversing a finding — that requires a different mechanism entirely.

    Not every publisher enforces this line consistently. COPE itself notes that “many journals do not distinguish between corrigendum or erratum but the note can explain if it is the publisher’s or authors’ error,” and some use “correction” as a catch-all. The US National Library of Medicine, which indexes PubMed, goes further still: it classifies both corrigenda and errata under a single “Published Erratum” tag for cataloguing purposes, regardless of who caused the error. Editors should not assume a downstream index preserves the author/publisher distinction they carefully applied upstream.

    Notice type Who caused the error Typical trigger Effect on the record
    Erratum Publisher/production Typesetting, misplaced figure, production-introduced typo Article stands; notice linked bidirectionally
    Corrigendum Author(s) Data entry error, wrong affiliation, miscalculation Article stands; notice linked bidirectionally
    Addendum Author(s) New, non-conflicting supplementary information Article stands; addendum appended
    Expression of Concern Unresolved Serious concern raised, investigation incomplete Article flagged pending outcome
    Retraction Author(s), publisher, or both Unreliable findings, misconduct, plagiarism, duplicate publication Article formally withdrawn; original remains visible with notice

    When Does an Error Require a Retraction Instead of a Correction?

    A retraction is warranted the moment an error stops being cosmetic and starts undermining the paper’s conclusions. COPE’s retraction guidance and the ICMJE Recommendations converge on the same threshold: if the reported findings can no longer be relied upon — whether from honest experimental error, data fabrication, image manipulation, or a flawed method that invalidates the results — a correction notice is insufficient and the paper must be retracted.

    COPE’s published criteria for retraction include clear evidence of unreliable findings, whether from major error or research misconduct; plagiarism or duplicate/redundant publication without proper attribution; and research that failed to meet ethical requirements for human or animal subjects. A single miscoded statistical test that changes a paper’s headline conclusion crosses this line; a mislabelled axis on a supplementary figure does not.

    This is a binary test editors should apply explicitly rather than by instinct: does the error change what a reader would conclude from the paper? If yes, retraction (or, where only part of the paper is compromised, a carefully scoped partial retraction) is the correct instrument — not a corrigendum dressed up to avoid reputational fallout.

    A Step-by-Step Decision Framework for Editors

    Use this sequence to route an identified error to the correct notice type:

    1. Does the error affect the validity, reliability, or interpretation of the results? If no, proceed to step 2. If yes, skip to step 4.
    2. Who introduced the error — the authors before submission, or the publisher during production? Author-origin errors that don’t affect conclusions become a corrigendum; publisher-origin errors become an erratum.
    3. Is the correction additive rather than corrective — new information that doesn’t conflict with the published record? Route to an addendum instead.
    4. Is there evidence of misconduct, fabrication, falsification, plagiarism, or duplicate publication, or does the error invalidate the paper’s central conclusions? If yes, this is retraction territory.
    5. Is an investigation still open but the concern serious enough that readers need an immediate warning? Issue an Expression of Concern as an interim notice while the inquiry proceeds.
    6. Publish the notice with bidirectional linking to the original article’s DOI, so indexers, Crossref, and reference managers can propagate the correction status automatically.

    Every step should be documented in the journal’s editorial record even when the final notice seems self-evident — COPE explicitly cautions that authors must be informed before any correction or retraction notice is published, and that agreement on wording, while ideal, “is not a requirement.”

    Expressions of Concern, Partial Retractions, and Addenda

    Three intermediate instruments sit between “leave it alone” and “retract in full,” and editors under-use all three.

    • Expression of Concern: issued when an investigation into a paper’s integrity is under way but unresolved, and the concern is serious enough that readers need warning before the inquiry concludes. It is explicitly a holding notice, not a verdict.
    • Partial retraction: withdraws only the compromised portion of a paper — a single figure, dataset, or claim — while leaving the remainder of the record intact. COPE guidance treats this instrument cautiously, since a partially retracted paper can be difficult for readers to interpret correctly; it should be reserved for cases where the surviving content is genuinely independent of the flawed portion.
    • Addendum: adds new, non-conflicting information to a published paper — for example, a dataset the authors did not originally deposit. It corrects nothing; it supplements.

    Since 2023, Crossref has stewarded the Retraction Watch Database and integrated its records into Crossref metadata, making retraction status machine-discoverable directly from an article’s DOI rather than requiring a manual search. This matters operationally: a research office checking whether a cited paper has been retracted, corrected, or flagged with an Expression of Concern can now query that status programmatically instead of relying on the journal’s own website staying current.

    Redaction vs Retraction: Why the Terms Get Confused

    “Redaction” and “retraction” are frequently conflated in search queries and in casual use, but they describe unrelated actions. Redaction means removing or obscuring specific sensitive content from a document — a patient identifier, classified information, a legally privileged passage — while leaving the rest of the document intact and published. Retraction means formally withdrawing an entire scholarly article from the reliable literature because its findings can no longer be trusted.

    A research office redacts personal data from a dataset before deposit; it does not redact a published paper. If the concern is that a paper’s findings are unreliable, the applicable mechanism is a correction (corrigendum/erratum) or a retraction — never a “redaction” of the article itself. Editors and compliance staff should treat any external query using “redact” in connection with a published paper as a signal to clarify which of the five instruments above the requester actually means.

    Common Questions About Corrections and Retractions

    What Is the Difference Between Addendum and Corrigendum?

    An addendum adds new, non-conflicting information to a published paper, such as a supplementary dataset the authors omitted at submission. A corrigendum corrects an existing error the authors introduced — incorrect data, a wrong affiliation, a miscalculation. Addenda supplement the record; corrigenda fix it.

    What Is the Purpose of a Corrigendum?

    A corrigendum exists to correct an author-introduced error that appears in the body of a published article — flawed data, a misreported figure, or an incorrect reference — without withdrawing the paper. It preserves the article’s validity while making the published record accurate and permanently linked to the original.

    What Is the Difference Between Errata and Correction?

    “Correction” is the umbrella term covering any post-publication fix that doesn’t invalidate a paper’s conclusions. “Errata” traditionally denotes production-side corrections specifically, but the US National Library of Medicine indexes all such fixes — author or publisher caused — under a single “Published Erratum” category, regardless of origin.

    What Does an Erratum Mean?

    An erratum is a formal notice correcting an error the publisher or journal introduced during production — typesetting, a misplaced figure, a formatting mistake — rather than an error present in the authors’ original submission. It confirms the underlying research and conclusions remain valid.

    Implications for Research Offices

    For institutional research offices and research integrity staff, the practical stakes of this distinction are higher than the terminology suggests. Grant reporting, tenure and promotion dossiers, and REF/assessment-exercise submissions all treat “retracted” very differently from “corrected” — a retraction can trigger funder inquiries and institutional misconduct review, while a corrigendum typically does not. Misclassifying a serious, conclusion-altering error as a corrigendum to avoid that scrutiny is itself a publication-ethics failure, not a shortcut.

    Research administrators should build a standing check into any publication-tracking workflow: query DOIs against Crossref’s retraction metadata at the point of citation-count reporting or dossier compilation, not only at initial publication, since correction and retraction notices can post months or years after the original article.

    The Bottom Line

    The corrigendum/erratum boundary is a question of who caused the error; the correction/retraction boundary is a question of whether the paper’s conclusions still hold. Editors who apply both tests explicitly — and who reach for an Expression of Concern when an investigation is still open — protect the scholarly record more effectively than those who default to whichever notice feels least reputationally costly. As Crossref’s retraction metadata becomes a standard citation-checking layer, the cost of misclassification is no longer just reputational; it is now machine-visible across the scholarly infrastructure that research offices, funders, and publishers all query.

    For related terminology, consult the CASRAI Dictionary of research-administration terms, and see how correction and retraction tracking fits into wider institutional workflows on the research administration hub.